<DOC>
	<DOCNO>NCT00562952</DOCNO>
	<brief_summary>Increased level NT-proBNP know increase risk cardiac event diabetic patient . The way around , patient normal value excellent prognosis short-term . We intend study proof hypothesis , whether possible decrease NT-proBNP level intensify cardiac prevention care We aim patient , already elevate level , although history cardiac disease . This decrease NT-proBNP translate consequently decrease cardiac event</brief_summary>
	<brief_title>Nt-proBNP Guided Primary Prevention CV Events Diabetic Patients</brief_title>
	<detailed_description>Patients diabetes mellitus several-fold increase risk cardiovascular disease ( 1-3 , 16 ) . Early diagnosis thesis disease might prevent least postpone occurence clinical manifest CAD CHF . Multifactorial intervention , special interest cardiac disease proven beneficial diabetic patient ( 4 ) . Whether patient benefit multi-drug supply include lipid lower agent antihypertensive drug know . Thus , special population define , profit . E.g . STENO- study population ( 4 ) consist patient microalbuminuria . Microalbuminuria know good marker outcome population ( 5 ) . Consistently fact microalbuminuria good marker long-term outcome , STENO-Investigators find long-term benefit ( average 7.8 year ) multi-factorial intervention special population . We recently find , Nt-proBNP ( Roche ) excellent short-term predictor cardiovascular event death ( 10 month average ) diabetic without history cardiac disease ( 6 ) , already know long-term ( 7-10 ) . Patients normal range 10 % risk first occurrence cardiac disease death within short time . The advantage Nt-BNP marker risk base fact , increase cardiac disease dependent severity . Our data reveal Nt-proBNP superior know marker . The limitation traditional surrogate marker risk diabetic patient recently discuss joint statement American Heart Diabetic Associations ( Diabetes Care 2007 Januar ) .Whether lower blood pressure cholesterol optimal surrogate therapeutic success questionable . The Jikei Heart study ( 11 ) nicely show comparable decrease blood pressure several treatment group , tremendous difference outcome . The heart failure paradoxon demonstrate , population patient low blood pressure ( 12 ) low cholesterol ( 13 ) bad prognosis . And heart failure immanent diabetes . On hand decrease Nt-proBNP therapy know excellent marker outcome ( 14 ) . We hypothesize , include diabetic patient without history cardiac disease increase level Nt-BNP excellent short-term risk-population prevention therapy . And , decrease Nt-proBNP level optimize therapy good marker success decrease risk future imminent event Patients randomize two group : Group A : Patients care cardiologic unit . In accordance guideline investigation perform proof existence manifest cardiac disease . Further treatment tailor minimize individual risk profile accordance guideline ( 15 ) . The main therapeutic focus decrease Nt-proBNP 50 % value index time normal value . Secondly , special focus set optimize anti-hyperglycemic therapy diabetologist ( treatment target ) . Further guideline-recommended medical treatment initiate yet start ( contraindication exist patient receive oral anti-platelet therapy lipid lower medication ) . After obtain informed consent , patient investigate clinical appropriate . Performance echocardiography mandatory exclude aortic stenosis proof existence heart failure- recommend guideline . Group A : patient receive schedule visit monthly optimize pharmacologic treatment . After optimization visit perform clinical appropriate . In patient opportunity contact responsible person contact additionally telephone proof therapeutic success . As clinical appropriate every visit laboratory sample drawn , demographic data , data diabetic complication , pulse blood pressure take , test , whether treat goal reach ( see CRF detail ) . After one year schedule visit mandatory obtain laboratory sample , pulse blood pressure proof final therapeutic success base goal parameter , cholesterol , Nt-pro-BNP , heart rate , blood pressure , HBA1c . Group B patient care treat physician . The patient physician inform result investigation . After 1 year patient receive schedule visit , demographic data , data diabetic complication , lab sample , ECG , blood pressure take . Anamnesis hospitalization drug prescription obtain . If patient prematurely die , data obtain treat physician responsible institution . After two year data hospitalization death obtain telephone contact patient Melderegister Group A B . Observation period : 1 year Cohort : 150 patient group 1 . Stamler J. , Vaqccaro O. , Neaton JD. , Wentworth D. Diabetes , risk factor , 12year mortality men screen multiple risk factor intervention trial Diabetes Care 1993 ; 16:434-44 2 . Kannel WB , McGee DL . Diabetes cardiovascular risk factor : Framingham study . Circulation 1979 ; 59 ( 1 ) :8-13 . 3 . Almdal T , Scharling H , Jensen JS , Vestergaard H. The independent effect type 2 diabetes mellitus ischemic heart disease , stroke , death : population-based study 13,000 men woman 20 year follow-up . Arch Intern Med 2004 ; 164 ( 13 ) :1422-6 . 4 . Gaede P , Vedel P , Larsen N , Jensen G , Parving HH , Pedersen O. Multifactorial intervention cardiovascular disease patient type 2 diabetes . N Engl J Med 2003 ; 348:383-93 5 . Pambianco G. , Costacou T. , Orchard TJ The prediction major outcome type 1 diabetes : 12-year prospective evaluation three separate definition metabolic syndrome component estimate glucose disposal rate : Pittsburgh Epidemiology Diabetes Complications Study experience . Diabetes Care 2007 ; 30 ( 5 ) :1248-54 6 . Neuhold S , Nt-BNP short-term predictor cardiovascular hospitalization death diabetic patient without history cardiac disease compare classical risk-factors EASD Meeting 2007 Amsterdam 7 . Dawson A ; Jeyasslan S ; Morris AD ; Struthers AD . B—type natriuretic peptide alternative way assess total cardiovascular risk patient diabetes mellitus Am J Cardiol.2005 Oct 1 ; 96 ( 7 ) :933-4 8 . Tarnow L ; Plasma N-terminal pro-B-type natriuretic peptide mortality type 2 diabetes Diabetologia 2006 ; 49 : 2256-2262 9 . Gaede Hildebrandt P , Hess G , Parving HH , Pedersen O. P ; Plasma N-terminal pro-brain natriuretic peptide major risk marker cardiovascular disease patient type 2 diabetes microalbuminuria Diabetologia 2005 ; 48:156-163 10 . Bhalla MA ; Prognostic role b-type natriuretic peptide level patient type 2 diabetes mellitus JACC 2004 ; 44:1047-54 11 . Mochizuki S , Dahlöf B , Shimizu M , Ikewaki K , Yoshikawa M , Taniguchi I , Ohta M , Yamada T , Ogawa K , Kanae K , Kawai M , Seki S , Okazaki F , Taniguchi M , Yoshida S , Tajima N ; Jikei Heart Study group . Valsartan Japanese population hypertension cardiovascular disease ( Jikei Heart Study ) : randomise , open-label , blind endpoint morbidity-mortality study . Lancet . 2007 Apr 28 ; 369 ( 9571 ) :1431-9 . 12 . Lee T , Chen J , Cohen D , Tsao L. The association blood pressure mortality patient heart failure Am Heart J 2006 Jan ; 151 ( 1 ) :76-83 13 . Rauchhaus M , Clark AL , Doehner W , Davos C , Bolger A , Sharma R , Coats AJ , Anker SD . The relationship cholesterol survival patient chronic heart failure . J Am Coll Cardiol 2003 Dec 3 ; 42 ( 11 ) :1933-40 14 . Bettencourt P , Friões F , Azevedo A , Dias P , Pimenta J , Rocha-Gonçalves F , Ferreira A. Prognostic information provide serial measurement brain natriuretic peptide heart failure . Int J Cardiol . 2004 Jan ; 93 ( 1 ) :45-8 . 15 . Guidelines diabetes , pre-diabetes , cardiovascular disease : executive summary . The Task Force Diabetes Cardiovascular Diseases European Society Cardiology ( ESC ) European Association Study Diabetes ( EASD ) . Eur Heart J . 2007 Jan ; 28 ( 1 ) :88-136 .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Bisoprolol</mesh_term>
	<criteria>Age &gt; 18 year Known Diabetes mellitus &gt; 6 month Increased NtproBNP 125pg/ml Given inform consent Disease diabetes , life expectancy 1 year patient suffer chronic infection malignant disease Women childbearing age without contraceptive History cardiac disease systemic cortisone treatment patient chronic acute hemodialysis , ultra filtration peritoneal dialysis</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Natriuretic peptide</keyword>
	<keyword>Prognosis</keyword>
	<keyword>Diabetes</keyword>
	<keyword>Heart failure</keyword>
	<keyword>Heart disease</keyword>
</DOC>